Transforming medical devices for improved patient outcomes

Arthur J. Benvenuto
Chairman & Chief Executive Officer, Micell Technologies

Art serves as Chairman and Chief Executive Officer, a position he has held since leading the formation of Micell’s biomedical business in 2006.

Prior to being named to his current role, Art served as Chairman, Life Sciences for RA Capital Group, an advisor to venture capital firms, as well as a board member of other biotech and medical device companies. He was also an early principal and the Chairman & CEO of Advanced Tissue Sciences, Inc. (ATS), a public biotechnology firm focused on the field of tissue engineering. Prior to joining ATS, Art served as President and General Manager of Eli Lilly Canada, Inc. and was President & CEO of IVAC Corp., a medical device company previously owned by Eli Lilly (now part of Care Fusion/BD). Art also held various marketing and sales management positions within the Pharmaceutical Division of Lilly as well as within the medical device subsidiary, IVAC. He holds a B.S. in Pharmacy and an honorary Doctor of Science from St. John’s University.

Art’s previous board appointments include: Scripps Institute of Medicine and Science; The Scripps Research Institute; Scripps Memorial Hospital Foundation (where he served as President); Project HOPE, an international health and education foundation; La Jolla Cancer Foundation (now Sanford-Burnham Medical Research Institute); Board of Overseers for the University of California, San Diego; Governor’s Council on Biotechnology (California); San Diego Economic Development Corporation; City National Bank (San Diego Advisory Board); and BIOCOM (San Diego), where he was a founding board member.  Art has acted as a former board member and advisor to certain other privately-held and publicly-traded biomedical companies.